GOED News Alerts: Analysis on events affecting EPA and DHA Markets

Positive Meta Analysis on Omega-3s and Blood Pressure Published

March 7: Results from a positive meta-analysis linking intake of EPA and DHA to a drop in blood pressure was published today in the American Journal of Hypertension. The study, which was commissioned by GOED and completed by Exponent Inc. and Van Elswyk Consulting, Inc., included 70 randomized controlled trials in both normotensive and hypertensive subjects.
 
Key takeaways for the study are:
 
Omega-3 fatty acids can be as effective or more effective in lowering blood pressure than other lifestyle interventions, including restricting sodium and alcohol intake and increasing physical activity.
  • Among all subjects, systolic blood pressure decreased by an average 1.52 mm Hg and diastolic blood pressure by 0.99 mm Hg.
  • Among those with hypertension, the effect was even greater, with an average reduction in systolic blood pressure of 4.51 mm Hg and an average reduction in diastolic BP of 3.05 mm Hg.
  • Among normotensive subjects, the drop in SBP was an average of 1.25 mm Hg and in DBP, 0.62 mm Hg.
  • In comparison, studies with non-treated individuals with high blood pressure have shown that dietary sodium reduction reduces systolic blood pressure by 2-8 mm Hg, physical activity by 4-9 mm Hg and alcohol by 2-4 mm Hg. 
 
The decrease of 4.51 mm Hg in systolic blood pressure among those with high blood pressure could prevent an individual from having to take medication to control blood pressure levels or prevent an individual from moving toward a more progressive stage of hypertension. 
  • A decrease of 1.25 mm Hg in systolic blood pressure could prevent a pre-hypertensive from becoming hypertensive.
  • Another study found that each 2 mm Hg reduction reduces stroke mortality by 6 percent, coronary heart disease mortality by 4 percent and total mortality by 3 percent.
In conjunction with our public relations agency M Booth, GOED has issued a consumer press release and developed key messages for media explaining the importance of the study. M Booth is actively reaching out to key journalists to increase exposure on this story. We encourage members to share the press release and key points above with your colleagues, customers and consumers.
 
This meta-analysis is the basis for the health claim petition submitted to FDA last December.
 
 
 

Membership Update

March 1 — GOED welcomes four new companies to its membership, Daeduck FRD, Endeavor Therapeutics, Solix BioSystems, Inc. and Thetis Pharmaceuticals.

Daeduck FRD Food Division, which joined at the Base Level, is a South Korean producer of solvent-free krill oil. The main contact is Daniel Kang, who can be reached at daniel.kang@ddfrd.com.
 
Joining at the Base Level, Endeavor Therapeutics is a clinical-stage biopharmaceutical company leveraging its proprietary omega-3 composition to create new drugs. The main contact is John Dagnello, who can be reached at JDagnello@endeavorthera.com.
 
Also joining at the Base level, Solix BioSystems, Inc. is focused on the production of specialty algal products for the nutrition, personal care and aquaculture markets. The primary contact is Austin Maguire, who can be reached at austin.maguire@solixbiosystems.com.
 
Thetis Pharmaceuticals has joined at the Plus level and is an emerging pharmaceutical company with a portfolio of novel prescription drugs for the treatment of diabetes, hypertriglyceridemia and dyslipidemia. The primary contact is Gary Mathias, who can be reached at gmathias@thetispharma.com.
 
Also, Synthetic Genomics has upgraded to the Leadership Level. The primary contact is Jon Getzinger, who can be reached at jgetzinger@syntheticgenomics.com.
 
Twitter Account not yet Authorized
Follow us on Twitter
GOED Exchange
FAB ad
Linked In
Copyright © 2014 Global Organization for EPA and DHA Omega-3s, All rights reserved.
This content is designed for use by GOED members. It may not be distributed or reprinted without permission from GOED. To request permission, click here.